EKR names interim president, CEO

> EKR Therapeutics has announced that its executive chairman John Bailye has been appointed interim president and CEO replacing Howard Weisman, who is no longer with the company. Weisman will also no longer serve on EKR's board of directors. Release

> Human Genome Sciences has named David Southwell as CFO and EVP. Release

> Robert Shepard has been appointed CMO of Cornerstone Pharmaceuticals. Release

> Shengtai Pharmaceutical has appointed Hu Ye as its new CFO. Release

> Talaris Advisors has named Derek Lee as CFO and corporate development officer. Release

> Sandoz announced the appointment of Don DeGolyer as president of the company's U.S. operations and head of commercial operations for North America.

> Phillip Frost will serve as the new chairman of the board of Teva Pharmaceutical Industries after Eli Hurvitz indicated he wishes to be released from his duties. Moshe Many has stepped down from his role as interim chairman and has been appointed vice chairman. Release

> Protalix BioTherapeutics has reported that Eli Hurvitz is relinquishing his position as chairman and member of the board of directors.  The board has unanimously appointed longstanding member Zeev Bronfeld to serve as interim chairman. Release

> Charles Lannon has been named vice-chairman of the board at Kinex Pharmaceuticals. Release

> China Yongxin Pharmaceutical has announced that Hal Lieberman, Laura Philips, Bing Li and Jingang Wang were appointed to its board of directors as independent directors. Release

> 3SBio has announced changes to its board of directors. Liping Xu, company founder, executive director and VP, will retire from the board and her position as a company officer. Peiguo Cong will join the board and serve as an independent, non-executive director.

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.